Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Ultragenyx Pharmaceutical Inc. announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock.
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.
Shares of General Electric jumped as much as 13 percent in trading this morning after Danaher Corporation announced it was acquiring the conglomerate’s biopharma business, GE Biopharma, for $21.4 billion.
This morning, Ipsen said it entered into an agreement with Clementia will help the company continue its transformation that is part of a key strategic objective to accelerate its rare disease pipeline.
Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, said his company is the only biotech company that has successfully commercialized a gene therapy for a genetic disease in the United States.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
Promore Pharma AB (publ) publishes its Year-end report for 2018 at 09.00 CET on 26 February 2019
Strong Launch Continues With More than 550 Patients on Reimbursed Commercial Crysvita® (burosumab) Therapy in the United States at End of 4th Quarter 2018, 80 Percent Increase Versus End of 3rd Quarter